Purchase this article with an account.
M. A. Martinez-Castellanos, J. L. Domenzain-Afendulis, M. L. Hernandez-Rojas, A. Solis-Vivanco, N. Salazar-Teran, J. L. Villa-Aja, J. L. Guerrero-Naranjo, R. V. P. Chan, H. Quiroz-Mercado; Safety and Efficacy of Intravitreal Bevacizumab for Retinopathy of Prematurity. Invest. Ophthalmol. Vis. Sci. 2007;48(13):85.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
Retinopathy of prematurity (ROP) is a major cause of blindness in children. Although ablation of the retina with laser or cryotherapy reduces the incidence of blindness by suppressing neovasculariztion in ROP, the visual outcome after treatment remains poor. Vascular endothelial growth factor (VEGF) has an important role in the pathogenesis of ROP, and inhibition of VEGF expression in the neovascular phase may prevent the destructive effects of neovascularization.
Non comparative, prospective, interventinal case series. Bevacizumab was injected into the vitreous of patients with ROP in tree different groups: I- ROP that progressed to stage IVa or IVb and did not respond to conventional treatment (laser photocoagulation or cryotherapy), II- Patients who reached threshold ROP but there was no visualization of the fundus therefore making it difficult to treat with laser or cryotherapy, III- Patients who reached threshold ROP.
53 eyes of 13 male patiens and 14 female, with mean age of 4 months +/- 3 months, mean follow up was 6 months. We found neovascular regression in all patients, with one patient who had stage IVa ROP having spontaneous retinal reattachment after intravitreal injection of Bevacizumab.Reinjection was not necessary. There were no serious ocular or systemic adverse events.
In this series, we have found the use of intravitreal Bevacizumab to be safe and effective in the treatment of patients with retinopathy of prematurity. Further studies need to be performed in order to determine the safety and long term efficacy of intravitreal Bevacizmab for the treatment of ROP either as first line therapy or after failure of conventional therapy.
This PDF is available to Subscribers Only